Mixed Cellularity Classical Hodgkin Lymphoma (MC-cHL) — EBV-Associated, Expert Care & Cure Access

Mixed Cellularity Classical Hodgkin Lymphoma (MC-cHL) is the second most common subtype of classical Hodgkin Lymphoma, accounting for approximately 20–25% of all cases. It is named for its characteristic histology — a mixed cellular background containing Reed-Sternberg cells surrounded by a varied reactive infiltrate of eosinophils, plasma cells, histiocytes, neutrophils, and lymphocytes, without the fibrous bands that define Nodular Sclerosis cHL. MC-cHL is strongly associated with Epstein-Barr virus (EBV), which is found in more than 75% of cases, and with HIV infection.

Epstein-Barr virus infects B-cells and can transform them into malignant Reed-Sternberg cells when immune surveillance is impaired. MC-cHL has the highest EBV positivity rate among classical Hodgkin Lymphoma subtypes because it predominantly affects populations with high rates of childhood EBV infection (developing countries) and immunosuppressed individuals (HIV-positive patients) — two groups in whom immune control of EBV-infected B-cells is less effective. The EBV viral proteins LMP1 and LMP2A within RS cells activate pro-survival signalling pathways that contribute to malignant transformation and RS cell persistence.

MC-cHL is treated with the same framework as other classical Hodgkin Lymphoma subtypes. ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is the standard first-line chemotherapy for most patients. The number of cycles (2–6) depends on Ann Arbor stage and interim PET-CT (iPET2) response. For advanced-stage or high-risk disease, brentuximab vedotin + AVD (A+AVD) or escalated BEACOPP may be used. PET-CT-guided treatment adaptation (bleomycin omission in iPET2-negative patients) reduces toxicity in good responders. In HIV-positive patients, concurrent antiretroviral therapy (cART) is mandatory throughout chemotherapy.

HIV infection is common in MC-cHL and significantly affects management. HIV-positive patients require concurrent combination antiretroviral therapy (cART) to suppress viral load and enable immune recovery throughout chemotherapy. CD4 count guides the intensity of infection prophylaxis (PCP, antifungal, antiviral cover). In patients with very low CD4 counts, dose-modified ABVD may be necessary. Specialist HIV-oncology teams with experience in HIV-associated lymphoma are best placed to manage these patients, as drug interactions, infection risks, and immune reconstitution inflammatory syndrome require coordinated expertise.

Interim PET-CT is a metabolic imaging scan performed after the second cycle of chemotherapy to assess early treatment response. In Hodgkin Lymphoma, a negative iPET2 (Deauville score 1–3) predicts excellent outcomes and enables de-escalation — specifically, omission of bleomycin for the remainder of treatment, reducing the risk of bleomycin-induced lung damage without compromising cure rates. A positive iPET2 (Deauville 4–5) indicates early chemotherapy resistance and supports treatment escalation. iPET2-adapted strategies improve the balance between treatment efficacy and toxicity in both early and advanced MC-cHL.

For patients who relapse after or are refractory to first-line ABVD-based chemotherapy, the standard approach for transplant-eligible patients is salvage chemotherapy (typically platinum-based regimens such as DHAP or ICE) followed by high-dose chemotherapy and autologous stem cell transplantation (auto-SCT). Brentuximab vedotin maintenance after auto-SCT reduces relapse risk in high-risk patients. For patients who relapse after transplant or who are not transplant candidates, PD-1 checkpoint inhibitors (nivolumab, pembrolizumab) achieve response rates of approximately 65–70% and provide meaningful disease control.

Yes. MC-cHL has a bimodal age distribution with one peak in childhood and a second in adults over 55 years, in contrast to Nodular Sclerosis cHL which peaks predominantly in young adults. In children, MC-cHL is the most common Hodgkin Lymphoma subtype in developing countries and is typically highly EBV-positive. Paediatric MC-cHL is treated with paediatric Hodgkin Lymphoma protocols that differ from adult protocols in terms of chemotherapy regimens, radiation use, and late effects consideration — evaluation at a specialist paediatric oncology centre is important for children with this diagnosis.

Long-term effects of MC-cHL treatment include: pulmonary toxicity from bleomycin (reduced by iPET2-guided omission); anthracycline-related cardiac dysfunction; secondary malignancies (secondary AML from alkylating agents; breast cancer and thyroid cancer in patients who received chest radiotherapy); endocrine dysfunction (hypothyroidism after neck or mediastinal radiation); and fertility impairment. A survivorship care plan addressing surveillance schedules, cardiovascular risk reduction, and cancer screening recommendations is an important component of post-treatment care for all cHL survivors.

Yes. CancerFax connects MC-cHL patients with specialist lymphoma haematologists and HIV-oncology teams — reviewing biopsy reports including EBER EBV status, PET-CT staging, HIV test results, and treatment histories, then connecting patients with expert lymphoma programmes in India, Germany, South Korea, the UAE, and other countries internationally. We assist with second opinion coordination, guidance on A+AVD vs ABVD selection, brentuximab vedotin and PD-1 inhibitor access, autologous SCT coordination, and clinical trial identification for relapsed or refractory MC-cHL.